February 25, 2015
Daiichi Sankyo will reshuffle its organizations in Japan on April 1, looking to optimize its group structure before its flagship hypertension drug Olmetec (olmesartan) goes off patent starting next year. The move comes after the major Japanese drug maker launched...read more